AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts


  • AlloVir (ALVR) layoffs are coming for the majority of the company’s employees.
  • The firm intends to reduce its headcount by 95%.
  • This comes after three failed clinical trials last year.
AlloVir Layoffs - AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts

Source: Stock-Asso /

AlloVir (NASDAQ:ALVR) layoffs are in the news after the clinical-stage cell therapy company announced a massive number of job cuts.

AlloVir has revealed that a new round of layoffs will have it cutting 95% of its workforce. The company is doing so in an effort to reduce costs and preserve capital.

AlloVir notes that these job cuts will mostly take place in the first quarter of 2024 and should finish by April 15. It expects to suffer $13 million in one-time charges related to its headcount reduction. Most of these charges will come in Q1.

What’s Behind the AlloVir Layoffs?

These layoffs come after the company reported three failed clinical trials and ended the development of posoleucel. The discontinuation of posoleucel was announced in December after it failed to prove effective as a multi-virus-specific T-cell therapy.

News of the layoffs has ALVR stock falling 2.1% as of Friday morning. That comes alongside some 1.2 million shares changing hands. For the record, its daily average trading volume is about 1.6 million shares.

Investors seeking out even more of the most recent stock market stories are going to want to keep reading!

We have all of the hottest stock market news that traders are going to want to read about on Friday. Among that is what has stocks up today, Medical Properties Trust (NYSE:MPW) shares are down and Intellia Therapeutics (NASDAQ:NTLA) layoff details. You can catch up on all of these topics at the following links!

More Friday Stock Market News

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks. 

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Article printed from InvestorPlace Media,

©2024 InvestorPlace Media, LLC